A serial copolymerization procedure for manufacturing immunoadsorption walls as a potential unit in conjunction with hemodialysis filters.

A functional immunoadsorption wall for removal of beta-2-microglobulin has been made by partially incomplete two-stage copolymerization of acrylamide with immunoadsorbent. However, a substantial amount of immunoadsorbent needs to be flushed away after the copolymerization process. Thus, to enhance the utilization efficiency of immunoadsorbent, the flushed-away immunoadsorbent was further recovered, and the copolymerization was conducted in series to produce three consecutive immunoadsorption walls in this study. Preliminary removal tests show that similar removal patterns were obtained for these immunoadsorption walls. Although it is not timely to conclude that a clinically applicable immunoadsorption wall has taken shape, the development of a partially incomplete two-stage polymerization method and its associated techniques indeed provide a good basis for large-scale manufacturing immunoadsorption walls.

[1]  A. Kandus,et al.  Influence of Blood Flow on Adsorption of β2‐Microglobulin onto AN69 Membrane , 2008 .

[2]  Tsung-Hua Yang.  Development and characterization of a new stationary phase for an immunoadsorption wall. , 2005, Artificial organs.

[3]  Tsung-Hua Yang.  New approaches to the formation of a stationary phase in an immunoadsorption wall. , 2003, Artificial organs.

[4]  T. Bosch,et al.  State of the Art of Low‐density Lipoprotein Apheresis in the Year 2003 , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  Y. Kawaguchi,et al.  Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. , 2004, Artificial organs.

[6]  D. Falkenhagen,et al.  Pyrogen transfer across high- and low-flux hemodialysis membranes. , 2004, Artificial organs.

[7]  R. Langer,et al.  Single-chain antibody fragment-based adsorbent for the extracorporeal removal of beta2-microglobulin. , 2004, Kidney international.

[8]  I. Narita,et al.  Current clinical and pathogenetic understanding of β2‐m amyloidosis in long‐term haemodialysis patients , 2003, Nephrology.

[9]  S Mandolfo,et al.  Impact of Blood and Dialysate Flow and Surface on Performance of New Polysulfone Hemodialysis Dialyzers , 2003, The International journal of artificial organs.

[10]  R. Langer,et al.  A novel immunoadsorption device for removing beta2-microglobulin from whole blood. , 2001, Kidney international.

[11]  S. Moe,et al.  Effect of Hemodialysis Membranes on β2‐Microglobulin Amyloidosis , 2001 .

[12]  G. Ameer.  Modalities for the Removal of β2‐Microglobulin from Blood , 2001 .

[13]  J. Copley,et al.  Nontransplant Therapy for Dialysis‐Related Amyloidosis , 2001, Seminars in dialysis.

[14]  W. Owen,et al.  Pathogenesis of β2‐Microglobulin Amyloidosis: Role of Monocytes/Macrophages , 2001, Seminars in dialysis.

[15]  K. Ohashi.  Pathogenesis of β2‐microglobulin amyloidosis , 2001, Pathology international.

[16]  T. Drüeke.  β2‐Microglobulin and amyloidosis , 2000 .

[17]  M. Toepfer,et al.  DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. , 2000, Artificial organs.

[18]  I. Chu,et al.  The removal of beta-2-microglobulin by an immunoadsorption wall. , 1999, Artificial organs.

[19]  S. Stefoni,et al.  β2-Microglobulin and Low-Flux SyntheticDialyzers , 1998 .

[20]  Willy Lornoy,et al.  Remarkable Removal of Beta-2-Microglobulin by On-Line Hemodiafiltration , 1998, American Journal of Nephrology.

[21]  W. Kolff.  The early years of artificial organs at the Cleveland Clinic: Part I: artificial kidney and kidney transplantation. , 1998, ASAIO journal.

[22]  C. P. Sharma,et al.  Modified polyacrylamide microspheres as immunosorbent. , 1997, Artificial cells, blood substitutes, and immobilization biotechnology.

[23]  F. Gejyo,et al.  Dialysis-related amyloidosis and clinical significance of extracorporeal removal of beta2-microglobulin. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[24]  B. Dutrillaux,et al.  Comparative RB1 gene mapping in Homo sapiens, Pithecia pithecia, Macaca sylvana, and Cercopithecus aethiops tantalus. , 1996, Cytogenetics and cell genetics.

[25]  J. Floege,et al.  Beta-2-microglobulin-associated amyloidosis. , 1996, Nephron.

[26]  R. Vanholder,et al.  Middle molecules: toxicity and removal by hemodialysis and related strategies. , 1995, Artificial organs.

[27]  T. Miyazaki,et al.  Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. , 1995, Kidney international.

[28]  L. Vallar,et al.  Immunoadsorption procedure as a potential method for the specific beta 2-microglobulin removal from plasma of patients with chronic renal failure. , 1995, Journal of chromatography. B, Biomedical applications.

[29]  H. Schiffl,et al.  Beta-2-microglobulin removal by different hemodialysis membranes. , 1995, Contributions to nephrology.

[30]  H. Seo,et al.  Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. , 1994, The Journal of clinical investigation.

[31]  K. Ohashi,et al.  Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column. , 1992, Kidney international.

[32]  D. Ducassou,et al.  Microencapsulation of isolated pituitary cells by polyacrylamide microlatex coagulation on agarose beads. , 1991, Biomaterials.

[33]  W. Kolff.  Retrospective on artificial organs and the role of the Transactions--American Society for Artificial Internal Organs. , 1986, Artificial organs.

[34]  M Arakawa,et al.  A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. , 1985, Biochemical and biophysical research communications.

[35]  M. Galland,et al.  Serum β2-Microglobulin in Hemodialyzed Patients , 1978 .